Latest Insider Transactions at Better Therapeutics, Inc. (BTTX)
This section provides a real-time view of insider transactions for Better Therapeutics, Inc. (BTTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Better Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Better Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 09
2024
|
David P Perry Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
839,895
+25.79%
|
$0
$0.19 P/Share
|
|
Jan 09
2024
|
David P Perry Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
1,471,453
+48.27%
|
$0
$0.17 P/Share
|
|
Dec 18
2023
|
David P Perry Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
3,750
+3.44%
|
-
|
|
Dec 18
2023
|
Leslie A. Miller Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,587
+16.67%
|
-
|
|
Dec 18
2023
|
Andrew J. Armanino |
BUY
Grant, award, or other acquisition
|
Direct |
3,750
+18.0%
|
-
|
|
Dec 18
2023
|
Geoffrey M. Parker |
BUY
Grant, award, or other acquisition
|
Direct |
3,750
+0.36%
|
-
|
|
Dec 18
2023
|
Kristin Wynholds Chief Product Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,362
+10.1%
|
-
|
|
Dec 18
2023
|
Risa J Lavizzo Mourey |
BUY
Grant, award, or other acquisition
|
Direct |
3,750
+21.43%
|
-
|
|
Dec 18
2023
|
Richard H Carmona |
BUY
Grant, award, or other acquisition
|
Direct |
3,750
+2.33%
|
-
|
|
Dec 18
2023
|
Elder Granger |
BUY
Grant, award, or other acquisition
|
Direct |
3,750
+8.65%
|
-
|
|
Dec 18
2023
|
Mark A. Berman Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,362
+5.36%
|
-
|
|
Dec 18
2023
|
Frank Karbe Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
62,500
+10.61%
|
-
|
|
Jul 27
2023
|
David P Perry Executive Chairman |
BUY
Open market or private purchase
|
Indirect |
1,233,045
+8.64%
|
$0
$0.73 P/Share
|
|
Jul 27
2023
|
Geoffrey M. Parker |
BUY
Open market or private purchase
|
Direct |
685,025
+39.99%
|
$0
$0.73 P/Share
|
|
Jul 27
2023
|
Frank Karbe Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
137,005
+24.19%
|
$0
$0.73 P/Share
|
|
Jul 27
2023
|
Elder Granger |
BUY
Open market or private purchase
|
Direct |
34,251
+48.86%
|
$0
$0.73 P/Share
|
|
Jul 27
2023
|
Andrew J. Armanino |
BUY
Open market or private purchase
|
Indirect |
274,010
+27.34%
|
$0
$0.73 P/Share
|
|
Jul 27
2023
|
Mark A. Berman Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
54,802
+12.37%
|
$0
$0.73 P/Share
|
|
May 16
2023
|
Elder Granger |
BUY
Open market or private purchase
|
Direct |
600
+27.27%
|
$0
$0.87 P/Share
|
|
Apr 10
2023
|
David P Perry Executive Chairman |
BUY
Open market or private purchase
|
Indirect |
4,969,697
+30.08%
|
$0
$0.82 P/Share
|
|
Apr 10
2023
|
Andrew J. Armanino |
BUY
Open market or private purchase
|
Indirect |
303,030
+40.01%
|
$0
$0.82 P/Share
|
|
Apr 10
2023
|
Geoffrey M. Parker |
BUY
Open market or private purchase
|
Direct |
303,030
+46.9%
|
$0
$0.82 P/Share
|
|
Apr 10
2023
|
Frank Karbe Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
242,424
+45.33%
|
$0
$0.82 P/Share
|
|
Apr 05
2023
|
Mark A. Berman Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
101,450
+23.33%
|
-
|
|
Apr 05
2023
|
Mark Heinen Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,000
+27.87%
|
-
|
|
Apr 05
2023
|
Kristin Wynholds Chief Product Officer |
BUY
Grant, award, or other acquisition
|
Direct |
101,450
+33.62%
|
-
|
|
Nov 30
2022
|
Mark Heinen Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,723
+15.5%
|
$15,723
$1.24 P/Share
|
|
Nov 30
2022
|
Kristin Wynholds Chief Product Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,781
+3.69%
|
$3,781
$1.24 P/Share
|
|
Sep 16
2022
|
David P Perry Executive Chairman |
BUY
Open market or private purchase
|
Direct |
39,156
+27.83%
|
$78,312
$2.07 P/Share
|
|
Sep 15
2022
|
David P Perry Executive Chairman |
BUY
Open market or private purchase
|
Direct |
10,844
+14.81%
|
$10,844
$1.99 P/Share
|
|
Sep 15
2022
|
Frank Karbe Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
50,000
+50.0%
|
$100,000
$2.09 P/Share
|
|
Sep 13
2022
|
Mark Heinen Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
26,132
+27.18%
|
$26,132
$1.94 P/Share
|
|
Sep 12
2022
|
Mark Heinen Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
23,868
+35.24%
|
$23,868
$1.94 P/Share
|
|
Jun 24
2022
|
Mark Heinen Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
2,280
+50.0%
|
$2,280
$1.75 P/Share
|
|
Jun 14
2022
|
Andrew J. Armanino |
BUY
Open market or private purchase
|
Indirect |
15,000
+50.0%
|
$15,000
$1.39 P/Share
|
|
Jun 13
2022
|
Geoffrey M. Parker |
BUY
Open market or private purchase
|
Direct |
25,000
+38.46%
|
$25,000
$1.45 P/Share
|
|
Jun 10
2022
|
Mark Heinen Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+20.0%
|
$5,000
$1.56 P/Share
|
|
Jun 09
2022
|
Andrew J. Armanino |
BUY
Open market or private purchase
|
Indirect |
25,000
+14.18%
|
$25,000
$1.65 P/Share
|
|
May 31
2022
|
Kristin Wynholds Chief Product Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,023
+5.02%
|
$5,023
$1.54 P/Share
|
|
May 27
2022
|
Justin Zamirowski Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,677
+4.35%
|
$0
$0.5 P/Share
|
|
May 16
2022
|
Justin Zamirowski Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
35,236
+50.0%
|
$0
$0.5 P/Share
|
|
Mar 31
2022
|
Kevin J Appelbaum Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
2,500
+28.57%
|
$2,500
$1.97 P/Share
|
|
Mar 31
2022
|
Mark Heinen Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+25.0%
|
$5,000
$1.98 P/Share
|
|
Mar 29
2022
|
Geoffrey M. Parker |
BUY
Open market or private purchase
|
Direct |
15,000
+50.0%
|
$30,000
$2.15 P/Share
|
|
Mar 29
2022
|
Andrew J. Armanino |
BUY
Open market or private purchase
|
Indirect |
40,000
+24.05%
|
$80,000
$2.14 P/Share
|
|
Dec 21
2021
|
Risa J Lavizzo Mourey |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$40,000
$4.6 P/Share
|
|
Dec 20
2021
|
Kevin J Appelbaum Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+21.05%
|
$4,000
$4.6 P/Share
|
|
Dec 15
2021
|
Kevin J Appelbaum Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
750
+21.43%
|
$3,000
$4.71 P/Share
|
|
Dec 15
2021
|
Mark Heinen Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
2,333
+18.92%
|
$9,332
$4.7 P/Share
|
|
Dec 14
2021
|
Geoffrey M. Parker |
BUY
Open market or private purchase
|
Indirect |
20,000
+27.27%
|
$80,000
$4.94 P/Share
|